Biomarin Pharmaceutical Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Good afternoon, everyone. My name is Gena Wang. I'm SMID Cap Biotech Analyst at Barclays. Welcome to our fifth Gene Editing & Gene Therapy Summit.
It is my great pleasure to introduce our next speaker, Hank Fuchs, President Worldwide R&D from BioMarin. Hank, maybe I'll hand over to give a brief overview, then I will dive into the Q&A.
Thanks very much, Gena. It's great to be here. and we appreciate the opportunity with just a few weeks remaining in 2021, we look forward to 2022 with great excitement. As the Head of R&D, I'm very pleased with the execution of our pipeline pivot from predominantly ultra-rare disorders to products that address more prevalently affected conditions. Our mission to translate genetic discoveries and transformative medicines has not changed, but the ability to leverage our deep foundational knowledge is changing the breadth and depth of our next
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
